Minor
MorningLyte · Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5
Enrollment closed, study ongoing
Also in this update: Trial sites reduced: 116 → 111 locations
The Lymphoma Academic Research OrganisationPhase 3 NCT06284122 Registry history of NCT06284122 on ClinicalTrials.gov (opens the registry)